Summary The expression of basic fibroblast growth factor (bFGF) and two of its receptors, FGFR1 and FGFR2, was detected using the polymerase chain reaction, and quantified by comparison to the relative amount of product obtained following co-amplification of the ubiquitous glyceraldehyde phosphate dehydrogenase transcript. Varying levels were found in the vast majority of both cancer and non-malignant breast biopsies as well as in samples of several other normal human tissues. Significantly less bFGF was present in cancers (P< 0.0001). Similarly, FGFR2 product was also much less in cancer tissues (P = 0.0078), as was FGFR1 (P = 0.002). FGFR1 levels in cancers tended to be higher in those which were oestrogen receptor positive (P<0.06). Amplification of different coding regions showed evidence of variant forms of FGFR1 RNA. Cancers appeared to have a significantly greater proportion of PCR product corresponding to the region between the third immunoglobulin like domain and the tyrosine kinase domain (P = 0.046). Differential expression was observed in breast cell lines, with bFGF in the normal derived HBL100, HBR SVI.6.1 and 184A1 but little or none in ZR-.75-1, MCF-7, T47D and MDA-MB-231. FGFR1 was present in most of these but FGFR2 was absent from T47D, MDA-MB-231 and HBL100. ZR-75-1 cells had a marked preponderance of FGFRI variants lacking part of the coding sequence.
The fibroblast growth factors (FGF), acidic FGF, basic FGF, int-2, hst/k-FGF, FGF 5, FGF 6 and keratinocyte growth factor (Klagsburn et al., 1986; Gospodarowicz et al., 1986; Dickson & Peters, 1987; Tiara et al., 1987; Delli Bovi et al., 1987; Zhan et al., 1988; Rubin et al., 1989; Marics et al., 1989) are a group of structurally related heparin binding polypeptide mitogens of widespread tissue distribution that induce proliferation of most cultured cells derived from embryonic mesoderm and neuroectoderm, including endothelial cells. Sharing 33-55% amino acid sequence identity and similar genomic organisation, they are involved in differentiation, embryogenesis, angiogenesis, chemotaxis and wound healing (Baird et al., 1987; Burgess & Maciag, 1989; Rifkin & Moscatelli, 1989; Maxwell et al., 1991) .
The hst and int-2 genes are co-amplified in a minority of human cancers, including breast (Theillet et al., 1989) but are poorly expressed. Acidic FGF expression is largely confined to neural tissues (Maxwell et al., 1991) whereas bFGF is ubiquitously distributed in normal human tissues (CordonCardo et al., 1990) , and in neural and squamous carcinomas, melanomas, osteosarcomas and hemangiomas (Takahashi et al., 1990; Shulze-Osthoff et al., 1990) . It is mitogenic for cultured mammary epithelial cells (Takahashi et al., 1989; Briozzo et al., 1991) and stimulates plasminogen activator (Lopez et al., 1986) which has been implicated in tumour invasion . Basic FGF has been immunolocalised in myoepithelial cells in benign breast and around intraduct carcinomas but was not detected in cancer cells (Gomm et al., 1991) .
The cellular response to these peptides is mediated through cell surface receptors composed of several extracellular immunoglobulin-like domains, a transmembrane region and an intracellular portion exhibiting intrinsic tyrosine kinase activity (Ruta et al., 1988; Lee et al., 1989; Safran et al., 1990) . Several distinct human genes named fig (FGFR1), bek (FGFR2), FGFR3 and K-sam (also FGFR2) bearing sequence homology to the chick FGF receptor gene (Lee et al., 1989) have been described (Dionne et al., 1990; Keegan et at, 11991 fattori et al., 1990) . A fourth gene termed FGFR4 hi also been reported (Partanen et al., 1991) . For the FO;FRI (Fujita et al., 1991) and probably also the FGFR2 (Dionne et al., 1990) , multiple forms of the receptor have been found comprising deletions within the extracellular domain, apparently generated by alternatively spliced mRNA's. Variant forms of the murine receptor appear to be developmentally regulated in neuroepithelium (Reid et al., 1990) .
In view of the diversity of action of the FGF peptides and the apparent complexity in the processing of receptor isoforms, there is considerable potential for their involvement in malignant transformation, as well as in normal cellular interactions. In this report we describe the results of a study designed to assess the expression of bFGF and of the FGFR1 and FGFR2 receptors in human breast tissues. We have compared the levels of these mRNA's in normal/benign and cancerous biopsies with cultured cell lines and a variety of normal human tissues. Our findings indicate widespread expression of bFGF, FGFRI and FGFR2, and suggest that many of these tissues contain variant FGFR1 receptor mRNA's in differing ratios. firmation of diagnosis, samples were dissected for material of interest and snap frozen and stored in liquid nitrogen. Tissues were examined from 66 primary carcinomas from patients aged between 29 and 79 years. Details of these patients are given in Table I . The non-malignant samples were composed of tissue removed from adjacent to cancer or from benign tumour. Other tissues used in this study were either surgical biopsy specimens or autopsy material.
Probes
The following cDNA inserts were used in this study: bFGF, 0.475 Kb excised from PBR322 (Abraham et al., 1986) FGFR1, 1.2 Kb excised from pGEMl (Ruta et al., 1988) and FGFR2 excised from pGEMl (Dionne et al., 1990) . Hybridisations were initially performed using these clones, but after the identity of the PCR products had been independently verified (i.e. by restriction enzyme anaylsis), we used PCR products for labelling.
Cell culture
The following breast cell lines (Engel & Young, 1978) (Stampfer & Bartley, 1985) were provided by Dr M. Stampfer. The gastric line, KATO 111, was from Dr T. Motoyama and was maintained in RPMI-1640 medium containing 10% foetal calf serum. Cell pellets from squamous carcinoma lines, SMN, GEE and PAP were obtained from Dr B. Gusterson. The rhabdomyosarcoma cell line, A204, was from Dr C. Cooper.
RNA isolation
Total cellular RNA was extracted from frozen tissue using the guanidinium isothiocyanate procedure (Chirgwin et al., 1979) , and a modified technique (Chomczynski & Saatchi, For blotting, gels were soaked briefly in 0.4 M NaOH, and DNA transferred onto Hybond N+ membrane in the same buffer. For hybridisation, filters were placed in roller bottles (Hybaid, UK) with a solution (60 p1lcm2) containing 50% (v/v) formamide, 0.1 % SDS, 5 x Denhardts (0.1 % each of polyvinylpyrrolidine, bovine serum albumin and ficoll), 5 mM EDTA, 75 mM NaCl and 250 ,sg ml-' denatured sonicated salmon sperm DNA, and incubated at 420 for 4-6 h. After this time, the relevant probe (either cDNA or PCR product) labelled with 32P-dCTP (to specific activities between 5.108 to I09 c.p.m. tg-' DNA) using the random primer method (Feinberg & Vogelstein, 1983 ) was added and incubation continued for a further 16-20 h. Filters were subsequently washed in 2 x SSC, 0.1% SDS at 20°C for 25 min with five changes of buffer, and then at 60-65°C in 0.1 x SSC, 0.1% SDS for 1 h, with two changes of buffer, and exposed to Amersham hyperfilm at -70°C using intensifying screens for periods between 30 min to several days. Band intensities were quantified using a laser densitometer.
Calculation of results
To compare the levels of expression of the bFGF, FGFR1 and FGFR2 genes in different samples, the densitometric readings were expressed as a ratio of the signal obtained for 12 cycles by hybridisation with 32P-labelled GAP cDNA, and increased linearly between 10-30 cycles. The mid-range, 18 cycles, was therefore selected for measuring GAP levels. Product accumulation was directly proportional to input template (3-200 ng RNA) after 18 cycles ( Figure 2 ). The reproducibility of the method was assessed in several experiments in which the RT product from 2 jig RNA from 13 (equivalent of 100 ng), from 2 1tg of 13 breast tumour RNA samples, were amplified through 18 cycles of PCR using GAP primers alone a, or in the presence of either FGFR1 B primers b, or of FGFR1 A and FGFR2 primers c. Aliquots were electrophoresed through 1.5% agarose, blotted only Hybond N+ membrane and hybridised with 32P-labelled GAP cDNA. Samples from a and b were run on the same gel and all three were hybridised and exposed to Hyperfilm together to achieve identical conditions. Control samples run in lanes marked with an asterisk, were from PCR reactions using RNA from mock RT reactions in which the reverse transcriptase had been ommitted. samples was divided into three portions and GAP amplified (a), alone (b), in the presence of FGFR1 primers B or (c), in the presence of FGFR1 A and FGFR2 primers (Figure 4 ): the variation was generally no greater than 50%, and the yield of GAP product was not greatly affected by the presence of the other primers. The yield of product from the FGFR1 and FGFR2 primers was reduced when GAP primers were present; but independently of template. The bFGF primers would only work on their own. Thus the optimal primer combinations used were (a), GAP and FGFR1 B (b), GAP and FGFR1 A and FGFR2 and (c), bFGF alone. In the latter case it was necessary to amplify the GAP control separately, but to maximise uniformity, complete double volume PCR mixes containing cDNA were divided into two tubes containing the respective primers, and amplification performed in adjacent wells of the Thermocycler. Forty cycles of PCR were optimal for detection of FGFR1 and FGFR2 and 30 cycles were most suitable for bFGF (Figure 4) , being within the linear stage of amplification. The slope of the linear part of the curve for each primer set was very similar, suggesting similar amplification efficiencies under the particular conditions we used. It should also be noted that this linear amplification For all the genes concerned we verified the identity of the product both by demonstrating hybridisation to the appropriate cDNA and by site specific cleavage with restriction enzymes (data not shown).
Expression of bFGF in breast tissues All 66 biopsies taken from patients with primary breast cancer, and 28 samples of either histologically normal tissue taken from adjacent to cancer or from patients with benign disease produced the expected 349 bp bFGF PCR product but the relative amounts varied greatly within both groups ( Figure 5 ). The mean ± s.e.m. for the cancers was 0.87 ± 0.12 as compared with 4.25 ± 1.03 for the non-malignant group; these being significantly different (P<0.0001).
Expression of FGFR2 in breast tissues
As with bFGF the individual levels of FGFR2 PCR product varied considerably in both cancers and non-malignant tissues alike ( Figure 5 ). Apart from the expected 578 bp fragment, hybridisation to two smaller bands was also observed; the origin of these is being investigated in the light of data which has appeared since this work was completed (Hou et al., 1991) . Only in three samples of cancer (<5%) was FGFR2 undetectable. Otherwise, there was a significantly greater level of amplified FGFR mRNA product in the normal tissues: means ± s.e.m. being 3.42 ± 0.46 and 9.92 ± 2.5 for cancers (n = 66) and non-malignant (n = 31) samples respectively (two-tailed probability = 0.0078).
Expression of FGFRI in breast tissues
We used two sets of primers to amplify either the region encoding the outermost immunoglobulin-like domain, or that spanning the sequence from the third immunoglobulin-like domain to, and including, half of the tyrosine kinase domain. Again a wide range of values were recorded for both cancers and non-malignant biopsies, with both pairs of primers ( Figure 5 ). With FGFRI B primers the two groups had means ± s.e.m. respectively of 0.97 ± 0.11 (n = 66) and 1.78 ± 0.39 which were not significantly different. Product was obtained with all samples. With FGFR1 A primers the means ± s.e.m. were 3.96 ± 0.62 (n = 66) and 12.6 ± 2.6 (n = 31) for cancers and non-malignant groups respectively. Basic FGF was present in heart, ileum, colon, kidney, stomach, adrenal gland, ovary, skin and thyroid with less than 5 fold differences between them, except for lung, which was much higher. The FGFR2 gene was also ubiquitously expressed, except in heart. The highest amount was present in the thyroid specimen.
All samples expressed FGFR1 with highest levels in skin ovary, and heart ( Figure 7 ). (Luqmani et al., 1992) to determine the precise cellular origin of the amplified RNA. The widespread presence of bFGF (Cordon-Cardo et al. 1990) suggests an important role in normal cellular function, but the lack of a signal peptide (Jaye et al., 1986) , precluding secretion in the classically recognised manner, has posed problems regarding its potential as a locally produced para/autocrine factor. However its appearance in conditioned media (Sato & Rifkin, 1988; Rifkin, 1991) and its association with the extracellular matrix (Saksela et al., 1988; Baird & Walicke, 1989) suggest that it may be externalised in conjuction with glycosaminoglycans which are also thought to modulate its biological activity (Ruoslahti & Yamaguchi, 1991; Yayon et al., 1991) .
Both FGFR1 and FGFR2 were expressed in all tissues except heart (an observation also made by Kornbluth et al. (1988) and Reid et al. (1990) ) and in the vast majority of the breast tissues. The wide range of values reflects the sensitivity of the PCR. In the light of growing evidence for the existence of truncated FGFR isoforms generated by alternative splicing, affecting all three structural domains, our results with the FGFR1 primers suggest that these commonly co-exist in the same tissue but in greatly varying proportions. Thus the ratio of PCR products obtained using the two FGFR1 primer sets reflects a greater frequency of FGFR mRNA's with deletions in the outermost Ig like domains in the cancer tissues as compared with the non-malignant breast samples but that the truncated form is present in both groups. Fujita et al. (1991) observed this to be the major form in placenta and found that it still mediated biologic response to both acidic and bFGF, suggesting that this domain is not required for binding but may play some other facilitatory role. Another placental cDNA encoding a soluble form of the placental receptor contains only the first two Ig like domains has been expressed in CHO cells and shown to undergo oligomerisation and retain binding activity (Duan et al., 1991) . A truncated FGFR2 cDNA encoding only the signal peptide and the first Ig domain followed by a termination codon, and an FGFR1 clone with only the two outer Ig like regions have also been reported (Dionne et al., 1990) . Spliced variants for the K-SAM (FGFR2) receptor have also been described in gastric carcinoma cells (Hattori et al., 1990 ). We found not only differential expression of FGFR2 and FGFR1 in the various cell lines studies, but also evidence of forms of the FGFR1 with deletions. ZR-75-1 cells appeared to have mRNA encoding only the external part. Hou et al. (1991) postulate the existence of up to 12 different variants of the FGFR1 receptor, which by extrapolation to the other three identified FGF receptors could extend this family to 48 isoforms. Johnson et al. (1991) have also recently described a number of different variants of FGFR1. The antisense primer of the FGFR1 A pair used in this study covers a region in which another variant involving a two amino acid deletion has been found: thus, lack of product with this primer may be due to such a variant in our samples, though it would have to be a predominant form. In the light of these recent findings, we are currently designing new primers to map these regions.
Other receptors also appear to display variant types. For example, developmentally regulated isoforms of the murine retinoic acid receptor beta generated by alternative splicing and differential promoter usage have also been described and may reflect functional specificities (Zelent et al., 1991) .
The presence of receptors on several breast cell lines has been demonstrated by ligand binding studies (Peyrat et al., 1991; Briozzo et al., 1991) and by Northern analysis, using 6 fig mRNA, in MCF7 cells (Lehtola et al., 1992) . Mitogenic effects have been noted on both MCF-7 cells and on immortalised mammary epithelial cells derived from breast reduction mammoplaasty (Valverius et al., 1990) . Primary monolayer cultures of breast epithelial cells grown out of fragmented biopsy tissue were reported to show a modest response to bFGF (more pronounced in cancer than in nonmalignant samples) but were unaffected by aFGF (Takahashi et al., 1989) . As none of these studies were concerned with the identity of the receptor, it is not yet clear which of the sub-types are involved. Our results suggest that FGFR1 mediated events could be studied using T47D, MDA-MB-231 and HBLIOO lines, all of which appear to be FGFR2 negative. The FGFR1 negative squamous line, PAP, could be used to study FGFR2 action. This of course does not take into account the presence of FGFR3 and FGFR4, the expression of which has yet to be determined.
A recent survey (Adnane et al., 1991) of 387 breast carcinomas showed amplification of both the FGFR1 and FGFR2 genes in about 12% of cases: FGFR1 amplification was correlated with nodal metastases and amplification of the HST, Int 2 and BCL I genes, and FGFR2 with c-myc. This work was supported by the Cancer Research Campaign. We thank Caroline Mortimer for help with the clinical data.
